Q4 2022 Results

Company overview Innovation: Pipeline overview Cardiovascular TNO155-SHP2 inhibitor NCT03114319 (CTNO155X2101) Indication Solid tumors (single agent) Phase 1 Financial review Immunology Phase Patients 255 Primary Outcome Measures Arms Intervention Target Patients Number of participants with adverse events Number of participants with dose limiting toxicities Drug: TNO155 Drug: TNO155 in combination with EGF816 (nazartinib) Adult patients with advanced solid tumors in selected indications Readout Milestone(s) Publication 2024 TBD 2023 priorities Innovation: Clinical trials Neuroscience Oncology Appendix Abbreviations Other 94 Investor Relations | Q4 2022 Results NOVARTIS | Reimagining Medicine

View entire presentation